Trial Profile

Safety in terms of MACEs and VTEs with JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib) versus anti-TNF alpha drugs (etanercept, adalimumab, infliximab, certolizumab pegol, golimumab) in patients with rheumatoid arthritis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baricitinib (Primary) ; Filgotinib (Primary) ; Tofacitinib (Primary) ; Upadacitinib (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Golimumab; Infliximab
Indications Rheumatoid arthritis
Focus Adverse reactions

30 Jun 2022 New trial record
04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com